Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease

Cancer Genomics and Proteomics

Volumn 11, Issue 6, 2014, Pages 279-294

  Kanaan, Yasmine M ^a   Sampey, Brante P ^b   Beyene, Desta ^a   Esnakula, Ashwini K ^c   Naab, Tammey J ^a   Ricks Santi, Luisel J ^d   Dasi, Sylvia ^a   Day, Agnes ^a   Blackman, Kwesi W ^a   Frederick, Wayne ^a   Copeland, Robert L ^a   Gabrielson, Edward ^e   Dewitty, Robert L ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b METABOLON INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HAMPTON UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

African American women; Metabolomic; Triple negative breast cancer

Indexed keywords

2 HYDROXYGLUTARIC ACID; AMINO ACID DERIVATIVE; ASPARAGINE; ASPARTIC ACID; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; GLUTAMIC ACID; ISOLEUCINE; LEUCINE; METHIONINE; PHENYLALANINE; SARCOSINE; VALINE; AMINO ACID; DIPEPTIDE; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENERGY METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENETIC ANALYZER; HUMAN; HUMAN TISSUE; MASS FRAGMENTOGRAPHY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST CANCER; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOME; METABOLOMICS; METHYLATION; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; PROCEDURES; TUMOR INVASION;

AFRICAN AMERICANS; AMINO ACIDS; BIOMARKERS, TUMOR; DIPEPTIDES; ENERGY METABOLISM; FEMALE; GLUTATHIONE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; METHYLATION; MIDDLE AGED; NAD; NEOPLASM INVASIVENESS; OXIDATION-REDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84912139595     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Rosen PP: Rosen's Breast Pathology. Second Edition. Philadelphia: Lippincott Williams & Wilkins, 2001.
2. Amirikia KC, Mills P, Bush J and Newman LA: Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer 117(12):2747-2753, 2011.
3. Cunningham JE and Butler WM: Racial disparities in female breast cancer in South Carolina: Clinical evidence for a biological basis. Breast Cancer Res Treat 88(2):161-176, 2004.
4. Elias AD: Triple-negative breast cancer: a short review. Am J Clin Oncol 33(6):637-645, 2010.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406(6797):747-752, 2000.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE and Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874, 2001.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL and Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423, 2003.
8. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D and Brown P: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161(6):1991-1996, 2002.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-74, 2004.
10. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, Ellis IO: Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18(1):26-35, 2005.
11. Gusterson BA, Ross DT, Heath VJ and Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7(4):143-148, 2005.
12. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF and Ellis IO: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495-506, 2006.
13. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA and Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 70(21):8309-8318, 2010.
14. Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL and Gribbestad IS: Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer 10:628, 2010.
15. Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešic M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn B V, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M and Denkert C: Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. J Proteome Res 11(2):850-860, 2012.
16. Dang CV, Lewis BC, Dolde C, Dang G and Shim H: Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 29(4):345-354, 1997.
17. Guillemette C, Belanger A and Lepine J: Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6(6):246-254, 2004.
18. German JB, Hammock BD and Watkins SM: Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 1(1):3-9, 2005.
19. German JB, Watkins SM and Fay LB: Metabolomics in practice: emerging knowledge to guide future dietetic advice toward individualized health. J Am Diet Assoc 105(9):1425-1432, 2005.
20. German JB, Bauman DE, Burrin DG, Failla ML, Freake HC, King JC, Klein S, Milner JA, Pelto GH, Rasmussen KM and Zeisel SH: Metabolomics in the opening decade of the 21st century: building the roads to individualized health. J Nutr 134(10):2729-2732, 2004.
21. Harrigan GG, Brackett DJ and Boros LG: Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. Mini Rev Med Chem 5(1):13-20, 2005.
22. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B and Yan H: Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108(8):3270-3275, 2011.
23. Evans AM, Dehaven CD, Barrett T, Mitchell M and Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the smallmolecule complement of biological systems. Anal Chem 81(16):6656-6667, 2009.
24. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q and Yu J: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910-914, 2009.
25. Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, Hanson RW, Kalhan SC, Ryals JA and Milburn MV: Analysis of the adult human plasma metabolome. Pharmacogenomics 9(4):383-97, 2008.
26. Dehaven CD, Evans AM, Dai H and Lawton KA: Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2(1):9, 2010.
27. Storey JD and Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100(16):9440-9445, 2003.
28. Whitfield JB: Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38(4):263-355, 2001.
29. Minois N, Carmona-Gutierrez D and Madeo F: Polyamines in aging and disease. Aging (Albany NY) 3(8):716-732, 2011.
30. Li CI, Malone KE and Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163(1):49-56, 2003.
31. O'Malley CD, Le GM, Glaser SL, Shema SJ and West DW: Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study. Cancer 97(5):1303-11, 2003.
32. Schneider EC, Zaslavsky AM and Epstein AM: Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 287(10):1288-1294, 2002.
33. McCarthy EP, Burns RB, Coughlin SS, Freund KM, Rice J, Marwill SL, Ash A, Shwartz M and Moskowitz MA: Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 128(9):729-736, 1998.
34. Miller BA, Hankey BF and Thomas TL: Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155(6):534-545, 2002.
35. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL and Prentice R: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439-448, 2005.
36. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS and Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502, 2006.
37. Gapstur SM, Dupuis J, Gann P, Collila S and Winchester DP: Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13, 239 cases. Cancer 77(8):1465-1471, 1996.
38. Joslyn SA: Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 73(1):45-59, 2002.
39. Furberg H, Millikan R, Dressler L, Newman B and Geradts J: Tumor characteristics in African-American and white women. Breast Cancer Res Treat 68(1):33-43, 2001.
40. Ihemelandu CU, Leffall LD Jr., Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L and Frederick WA: Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 14(10):2994-3003, 2007.
41. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 109(9):1721-1728, 2007.
42. Boros LG, Cascante M and Lee WN: Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 7(6):364-372, 2002.
43. Chen VW1, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C and Sobhan M: Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 3(2):127-135, 1994.
44. Beverly LN, Flanders WD, Go RC and Soong SJ: A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Public Health 77(3):351-353, 1987.
45. Liu Y: Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9(3):230-234, 2006.
46. Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91(1):47-53, 2004.
47. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C and Sukumar S: Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 10(6):2052-2057, 2004.
48. Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, Dohmae N, Field HI, Tsunoda T, Kobayashi T, Akasu T, Sugiyama M, Ohnuma S, Atomi Y, Ponder BA, Nakamura Y and Hamamoto R: Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res 72(13):3217-327, 2012.
49. Gribbestad IS, Sitter B, Lundgren S, Krane J and Axelson D: Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 19(3 A):1737-1746, 1999.
50. Sitter B, Sonnewald U, Spraul M, Fjosne HE and Gribbestad IS: High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 15(5):327-337, 2002.
51. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE and Gribbestad IS: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 19(1):30-40, 2006.
52. Cheng LL, Chang IW, Smith BL and Gonzalez RG: Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 135(1):194-202, 1998.
53. Bathen TF, Jensen LR, Sitter B, Fjösne HE, Halgunset J, Axelson DE, Gribbestad IS and Lundgren S: MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104(2):181-189, 2007.
54. Yang C, Richardson AD, Smith JW and Osterman A: Comparative metabolomics of breast cancer. Pac Symp Biocomput 181-92, 2007.
55. Spratlin JL, Serkova NJ, Eckhardt SG: Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15(2):431-440, 2009.
56. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G and Jung K: Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 185(2):706-711, 2011.
57. Schalken JA: Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 58(1):19-20, 2010.
58. Juhász C, Nahleh Z, Zitron I, Chugani DC, Janabi MZ, Bandyopadhyay S, Ali-Fehmi R, Mangner TJ, Chakraborty PK, Mittal S and Muzik O: Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies. Nucl Med Biol 39(7):926-932, 2012.
59. Sakurai K, Fujisaki S, Nagashima S, Maeda T, Shibata M, Gonda K, Tomita R, Suzuki S, Hara Y, Enomoto K and Amano S: Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis. Gan To Kagaku Ryoho 39(12):1776-1778, 2012.
60. Aune TM and Pogue SL: Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide. J Clin Invest 84(3):863-875, 1989.
61. Wei G, Defeo K, Hayes CS, Woster PM, Mandik-Nayak L, Gilmour SK: Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes. Cancer Res 68(7):2214-2222, 2008.
62. Manni A, Astrow SH, Gammon S, Thompson J, Mauger D, Washington S: Immunohistochemical detection of ornithinedecarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 67(2):147-156, 2001.
63. Deng W, Jiang X, Mei Y, Sun J, Ma R, Liu X, Sun H, Tian H, Sun X: Role of ornithine decarboxylase in breast cancer. Acta Biochim Biophys Sin (Shanghai) 40(3):235-243, 2008.
64. Moshier JA, Dosescu J, Skunca M, Luk GD: Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 53(11):2618-2622, 1993.
65. Cañizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P and Peñafiel R: Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 5(8):2035-2041, 1999.
66. Giskeødegård GF, Lundgren S, Sitter B, Fjøsne HE, Postma G, Buydens LM, Gribbestad IS and Bathen TF: Lactate and glycinepotential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed 25(11):1271-1279, 2012.